iDD Biotech (antibody assets) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
iDD Biotech (antibody assets) General Information
Description
Antibody therapeutics for the treatment of cancer. The monoclonal antibodies (mAb or moAb) are monospecific antibodies that are made by identical immune cells that are all clones of a unique parent cell, in contrast to polyclonal antibodies which are made from several different immune cells.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
- Bâtiment Accinov
- 317 avenue Jean Jaurès
- 69007 Lyon
- France
+33 04 00 00 00 00
iDD Biotech (antibody assets) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
iDD Biotech (antibody assets) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|